

Medical Drug Clinical Criteria

Subject: Fabrazyme (agalsidase beta)

Document #: CC-0021

Publish Date: 10/23/2023

Status: Revised

Last Review Date: 09/11/2023

Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical criteria](#)

[Document history](#)

Overview

This document addresses the clinical indications for Fabrazyme (agalsidase beta), a biosynthetic form of human alpha-galactosidase A enzyme. Fabrazyme is an enzyme replacement therapy (ERT) approved for the treatment of individuals with a lipid storage disorder called Fabry disease.

Fabry disease is an X-linked lysosomal (lipid) storage disorder related to a deficiency of the enzyme alpha-galactosidase A (α -Gal-A, also known as ceramide trihexosidase) required to metabolize lipids. Signs and symptoms of Fabry disease include burning sensations in the arms and legs (that worsens with exercise and hot weather), small, non-cancerous, raised reddish-purple blemishes on the skin, and clouding of the corneas. Other symptoms include decreased sweating, fever, and gastrointestinal difficulties. Lipid storage may lead to breathing and digestive problems, impaired circulation, and increased risk of cardiomyopathy, cerebrovascular accidents, and renal failure.

The American College of Medical Genetics (ACMG) (2011) and National Society of Genetic Counselors (NSGC) (2013) recommend screening for deficient α -Gal-A enzyme activity in males followed by confirmatory galactosidase alpha (*GLA*) gene sequencing. As α -Gal-A activity is unreliable in females, *GLA* gene sequencing should be performed for a confirmatory diagnosis.

ACMG states ERT is the standard of care for symptomatic individuals as it has shown improvements in the rate of renal dysfunction, pulmonary and gastrointestinal symptoms.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Fabrazyme (agalsidase beta)

Requests for Fabrazyme (agalsidase beta) may be approved if the following criteria are met:

- I. Documentation is provided that individual has a diagnosis of Fabry disease as defined with either of the following (ACMG, NSGC):
 - A. Documentation of complete deficiency or less than 5% of mean normal alpha-galactosidase A (α -Gal A) enzyme activity in leukocytes, dried blood spots, or serum (plasma) analysis; **OR**
 - B. Documented galactosidase alpha gene mutation by gene sequencing;

AND

- II. The individual to be treated has one or more symptoms or physical findings attributable to Fabry disease (ACMG), such as but not limited to:
 - A. Burning pain in the extremities (acroparesthesias); **OR**
 - B. Cutaneous vascular lesions (angiokeratomas); **OR**
 - C. Corneal verticillata (whorls); **OR**
 - D. Decreased sweating (anhidrosis or hypohidrosis); **OR**
 - E. Personal or family history of exercise, heat, or cold intolerance; **OR**
 - F. Personal or family history of kidney failure.

Continuation requests for Fabrazyme (agalsidase beta) may be approved if the following criteria are met:

- I. Individual has had a positive therapeutic response to treatment.

Fabrazyme (agalsidase beta) may not be approved for the following:

- I. Individual is using in combination with migalastat (Galafold) or pegunigalsidase alfa-iwxj); **OR**
- II. When the above criteria are not met and for all other indications.

Quantity Limits

Fabrazyme (agalsidase beta) Quantity Limit

Drug	Limit
Fabrazyme (agalsidase beta) 5 mg, 35 mg vial	1 mg/kg every two weeks

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

- | | |
|-------|---|
| J0180 | Injection, agalsidase beta, 1 mg (Fabrazyme) |
| S9357 | Home infusion therapy, enzyme replacement intravenous therapy; (e.g., Imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |

ICD-10 Diagnosis

- | | |
|--------|---------------------------|
| E75.21 | Fabry (-Anderson) disease |
|--------|---------------------------|

Document History

Revised: 09/11/2023

Document History:

- 09/11/2023 – Annual Review: Update non-approvable criteria to restrict use with pegunigalsidase alfa-iwxj. Wording and formatting changes. Coding Reviewed: No changes.
- 09/12/2022 – Annual Review: No changes. Coding Reviewed: No changes.
- 09/13/2021 – Annual Review: Update criteria to add continuation criteria. Coding review: No charges.
- 08/01/2021 – Administrative update to add documentation.
- 09/14/2020 – Annual Review: Update non-approvable criteria to restrict use with migalastat. Wording and formatting changes. Coding reviewed: No changes.
- 09/23/2019 – Administrative update to add drug specific quantity limit.
- 09/09/2019 – Annual Review: Minor wording and formatting changes. Coding reviewed: No changes.
- 08/17/2018 – Annual Review: Minor wording and formatting changes.

References

1. Biegstraaten M, Arngri msson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis*. 2015; 10:36. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383065/pdf/13023_2015_Article_253.pdf. Accessed: September 7, 2023.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 7, 2023.
3. DrugPoints  System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

4. Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. *J Inher Metab Dis*. 2011;34(2):509-514. Accessed September 7, 2023.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; Updated periodically.
6. Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors (NSGC). *J Genet Couns*. 2013;22(5):555-564. Focused Revision Sept. 2020. Accessed September 7, 2023.
7. Ortiz A, Germain D, Desnick R, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Gen Metab*. 2018;123(4):416-427. Accessed on September 7, 2023.
8. Schiffmann R, Hughes D, Linthorst G, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney Intl*. 2017;91:284-293. Accessed September 7, 2023.
9. Wang RY, Bodamer OA, Watson MS, Wilcox WR; American College of Medical Genetics (ACMG) Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. *Genet Med*. 2011;13(5):457-484. Accessed September 7, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association